Promising CLL Treatments: A Bcl-2 Inhibitor Update

Published on

Topics include: Treatment

Dr. John Seymour, a CLL researcher, shares an update about an ongoing trial using the Bcl-2 inhibitor ABT-199, which received a dose modification following safety concerns. Dr. Seymour explains Phase I trial data that demonstrates the therapy's balance of safety and efficacy as well its promising potential for combination with other agents.

View more programs featuring

Produced in association with


A lead investigator for one promising drug, ABT-199, is Dr. John Seymour from Australia.  We spoke to him to get an update on ABT-199. 

The first is that the effectiveness, the overall response rate, is holding up very well.  On the current analysis to be presented here, it's an 84 overall response rate with 23 percent complete remissions including a few patients assist on local laboratories that are negative MID. 

So the safety message is the second part.  There, as we've spoken with you previously, there had been a signal of concern about tumor lysis syndrome, so with modifications to a more gradual step-wise dose escalation and very vigilant prophylaxis, there have not been any more cases of tumor lysis syndrome that's seen.  So we're cautious but optimistic that that gradual dose escalation scheme, beginning at a dose of 20 milligrams on the first day with three sequential steps to the 400 milligram dose level, appears to be safe. 

The hope is that if we continue to see high complete remission rates, that we'll then be able to use a limited period of treatment rather than requiring indefinite ongoing therapy, which is currently the design of the study with ABT-199 as a single agent. 

So there are multiple elements to be considered, but we're still very much in the phase of learning how these components may fit together. 

I'm Andrew Schorr.  Thank you for joining us.  Remember, knowledge can be the best medicine of all.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

What to Consider When Choosing a CLL Treatment Path

Dr. Jeff Sharman, medical director of hematology research at The US Oncology Network, shares his perspective on the many treatment options available for patients with CLL.


Understanding CLL Clinical Trials

Dr. Adrian Wiestner, senior investigator in the laboratory of lymphoid malignancies at the National Heart Lung and Blood Institute (NHLBI), explores the clinical trial process.


CLL Research: How Far Have We Come? Where Are We Headed?

How far have we come in understanding and treating CLL? Where are we headed? Dr. Michael Keating, a world-renowned expert, explains.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on November 10, 2014